Toxocara canis is a common parasitic roundworm that infects dogs and can cause toxocariasis in humans. It is prevalent worldwide and poses a significant public health concern. Understanding the mechanisms of Toxocara canis pathogenesis is critical for developing effective control and prevention strategies.

C-type Lectin TES-32: A Key Player in Toxocara canis Pathogenesis
C-type lectin TES-32 is a highly conserved molecule that is expressed on the surface of Toxocara canis larvae. It plays a crucial role in host immune modulation, evasion, and tissue migration. TES-32 binds to host receptors and modulates the host immune response, allowing the parasite to evade immune surveillance.

Recent studies have shown that TES-32 is a promising vaccine candidate, and targeting this molecule could lead to the development of effective vaccines and control strategies.

MUC-3 and MUC-5: Glycoproteins Involved in Toxocara canis Pathogenesis.
MUC-3 and MUC-5 are glycoproteins that are expressed on the surface of Toxocara canis larvae. They play a critical role in host-parasite interactions, host immune modulation, and parasite migration.

MUC-3 and MUC-5 facilitate larval migration through host tissues by interacting with host extracellular matrix components. They also interact with host immune cells, modulating the host immune response and allowing the parasite to evade immune surveillance.

26 kDa Secreted Antigen: An Important Molecule in Toxocara canis Pathogenesis
The 26 kDa secreted antigen is a highly conserved molecule that is secreted by Toxocara canis larvae. It plays a critical role in host-parasite interactions, host immune modulation, and parasite migration.

The 26 kDa secreted antigen interacts with host extracellular matrix components, facilitating larval migration through host tissues. It also modulates the host immune response, allowing the parasite to evade immune surveillance.

The application of Toxocara canis cDNA and recombinant antigen in enzyme-linked immunosorbent assay (ELISA) for the diagnosis of toxocariasis is a promising new approach for the detection of toxocariasis. This technique uses cDNA and recombinant antigen to detect antibodies to T. canis in serum samples. By using cDNA, the ELISA can detect both IgG and IgE antibodies, which can provide additional diagnostic information. The use of recombinant antigen can also improve the sensitivity of the assay. Furthermore, the use of cDNA and recombinant antigen in the ELISA helps reduce the time and cost of diagnosis. This technique can be used to diagnose both acute and chronic cases of toxocariasis and may be useful in differentiating between the two forms of the disease.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.